KidImmune
A First-in-Class Predictive Test for Childhood Cancer.
Background
Cancer is the leading cause of death among children aged 0-19, with over 400,000 new cases diagnosed globally each year. Alarmingly, 90% of pediatric cancers are non-hereditary, and current screening options cannot identify predispositions to these cancers. KidImmune has identified a set of serum biomarkers that are common among patients with various pediatric cancers that may be applied for early cancer detection. In addition, based on on-going functional studies KidImmune may even be able to predict predisposition to future cancer. An approach enabling early identification of children at higher risk, allowing for enhanced surveillance and potential prevention—could transform pediatric cancer care.
Business Opportunity
We are seeking partnerships with industrial collaborators or licensees to develop and commercialize KidImmune. This test is poised to become the first-in-class solution for non-hereditary pediatric cancer prediction and prevention. With a projected global market potential and over 7 million annual tests in the EU and US alone, KidImmune has the potential of a transformative innovation in pediatric oncology, as a scalable, low-cost diagnostic solution with the potential to significantly enhance cancer outcomes and reduce healthcare costs.
Technology
KidImmune utilizes a panel of core biomarkers linked to cancer predisposition. The test identifies autoantibodies targeting those biomarkers. Unlike existing methods, KidImmune offers predictive screening for non-hereditary cancers, applicable across multiple cancer types, and at a fraction of the cost of genetic testing.
Project Status
Technology is undergoing validation in large-scale cohorts, including initial studies on its ability to detect cancer biomarkers years before diagnosis. The patent application PCT/EP2024/070894 is currently in the PCT phase.
Summary
KidImmune may represent a paradigm shift in pediatric oncology, addressing a critical unmet need. Its ability to identify cancer or cancer risk early not only could improve patient outcomes but also aligns with global healthcare initiatives for cost-effective, preventative care.
Contact Information
For more information or to discuss partnership or licensing opportunities, please contact:
Malgorzata Barczyk, PhD, Senior Innovation Manager
Email: mba@visinnovasjon.no
Phone: +47 480 82 052